Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.
Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- Check3 days agoChange DetectedThe website has updated the intervention details to include a verified status from June 2020 and added contact information for Dr. Sabine Zoechbauer-Mueller, while removing the previous intervention type and updating the revision to v2.14.0.SummaryDifference1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check39 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for those who can answer questions about joining the study, along with a reference to the Contacts and Locations section.SummaryDifference3%
- Check53 days agoChange DetectedThe website has added a 'Show less' feature while removing detailed options related to participant groups, interventions, and various data fields for downloads.SummaryDifference5%
- Check60 days agoChange DetectedSeveral key health-related websites, including MedlinePlus and DailyMed, have been removed from the monitored list, indicating a potential shift in focus or resource availability.SummaryDifference0.4%
- Check68 days agoChange DetectedThe website has been updated to version 2.12.2, adding several new resources related to genetics and lung cancer, as well as various data fields for study information, while removing the option to show less content.SummaryDifference6%
Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.